Comparing Anterior Segment Parameters During Pregnancy and Post-Pregnancy
NCT ID: NCT05175729
Last Updated: 2022-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2021-12-01
2022-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retinal Vascular Changes During Pregnancy
NCT06311617
Prognosis in Pregnant With COVID-19
NCT04409249
The Effect of Antenatal Corticosteroid on Umbilical Artery Doppler Velocimetry in IUGR
NCT05588986
Hormonal Changes in Early Pregnancy
NCT00340028
Ocular Findings in Women With Primary Antiphospholipid Syndrome
NCT03459508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As a result, it was stated that the refractive change was temporary and in favor of myopia. It is recommended to wait up to several weeks postpartum before prescribing new eyeglasses \[8\].
There are various reports about IOP in normal pregnant women. In most of these studies, a decrease was found in IOP during pregnancy. In a prospective study, a decrease in IOP was found in the second and third trimesters of pregnancy, and it was shown that this change returned in the first month postpartum.
Before planning an anterior segment surgeries such as cataract and refractive surgery, changes in pregnancy should be taken into account and attention should be paid to surgical timing. The aim of this study is to reveal whether there is a change in anterior segment parameters in pregnancy period
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant Group
First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
Comprehensive Ophthalmologic Examination
Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
Control group
Age-, sex-matched healthy volunteers
Comprehensive Ophthalmologic Examination
Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comprehensive Ophthalmologic Examination
Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant women with a gestational age less than 14 weeks in the first examination
* Having no systemic disease before and during pregnancy
* Having a spherical refractive error of less than 4 diopters, and/or had a cylindrical refractive error of less than 2 diopters
Exclusion Criteria
* Usage of systemic drugs or topical ocular drops
* Usage of exogenous hormones and entered menopause
19 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akdeniz University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Çisil Erkan Pota
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Çisil Erkan Pota, MD
Role: PRINCIPAL_INVESTIGATOR
Akdeniz University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akdeniz University Hospital
Antalya, Konyaaltı, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Study 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.